Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTOR-E1: Vicriviroc with Optimized ART in Treatment-Experienced CCR5-Tropic HIV Infection
2005-001057-21Phase 2Completed
- Sponsor
- Schering-Plough Research Institute
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vicriviroc in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Schering-Plough Research Institute. Primary endpoint: Change in HIV RNA at 48 weeks. Started Sep 2005; status: completed.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-001057-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001057-21.